| Autor: |
Lachin Rezadoost, Hamid Tayebi Khosroshahi, Farahnoosh Farnood, Parvin Sarbakhsh, Hossein Behzad, Afshin Gharakhani |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Pharmaceutical Sciences, Vol 30, Iss 3, Pp 304-311 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2383-2886 |
| DOI: |
10.34172/PS.2024.3 |
| Popis: |
Background: Pentoxifylline has anti-inflammatory effects in end stage renal disease (ESRD) patients and may play an important role in reducing inflammatory factors and improving quality of life (QoL) in hemodialysis (HD) patients. Methods: In this randomized placebo-controlled trial 88 chronic hemodialysis patients were divided into two groups with equal numbers. Intervention group received tablet pentoxifylline 400 milligrams and control group received the matching placebo, daily for 3 months. At baseline and after 3 months, inflammatory factors including serum levels of tumor necrosis factor-alpha (TNF-a) and C-reactive protein (CRP) were measured. Also, the Medical Outcome Study 36-Item Short-Form Health Survey (SF-36) quality of life (QoL) questionnaire was completed by each patient at the beginning and end of the study. Results: Significant reduction in serum levels of TNF-a, CRP as well as substantial improvement of all dimensions of QoL were observed in intervention group after 3 months of pentoxifylline treatment (P = 0.04; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
